Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2R,6R)-hydroxynorketamine
- Development stage
- Phase 2
- Lead developer
- National Institutes of Health
- Modality
- Small Molecules
01
Overview
(2R,6R)-Hydroxynorketamine is a metabolite of ketamine, known for its rapid antidepressant effects without the dissociative side effects associated with ketamine. It enhances AMPA receptor-mediated excitatory post-synaptic potentials and modulates metabotropic glutamate receptor subtype 2 (mGlu2) signaling. It also acts as a positive allosteric modulator of opioid receptors.
- Other names
- (2R,6R)-HNKHydroxynorketamine(2R,6R)-hydroxynorketamine hydrochloride
02
Targets
KOR (Kappa opioid receptor)DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)AMPAR (AMPA receptor)NMDAR (Glutamate receptor ionotropic, NMDA)GRM2 (mGluR2)
Beyond the preview
Go deeper on (2R,6R)-hydroxynorketamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (2R,6R)-hydroxynorketamine.